Navigation Links
Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy

ATLANTA, June 18, 2013 /PRNewswire/ -- regulated information — Global biopharmaceutical company UCB, Inc. and professional golfer Jeff Klauk today announced the launch of a new Pledge campaign for people with epilepsy and their loved ones. The Pledge empowers the millions of Americans living with epilepsy to take a stand and make a personal commitment to demand more: greater understanding of the condition, better collaboration with their health care team and additional partial-onset seizure control.  More information is available at

(Photo: )

Epilepsy is a chronic neurological condition that affects 3 million Americans and 65 million people worldwide.1 Anyone can develop epilepsy; it occurs across all ages, races and genders. Even though one in three adults knows someone with the disorder, it remains among the least understood chronic medical conditions.1

Jeff Klauk's experience with epilepsy has been a winding journey, dating back to 2006 when he first began experiencing seizures.  He had his first partial-onset seizure in 2010, but did not get an official epilepsy diagnosis until 2011. Klauk then began working with an epileptologist — a neurologist that specializes in epilepsy2 — to get additional control of the condition, and was started on a new treatment regimen that included the addition of the antiepileptic drug VIMPAT® (lacosamide) C-V to manage his partial-onset seizures. The most common adverse reactions reported with VIMPAT® include dizziness, headache, nausea, and double vision.

While Klauk's partial-onset seizures are typically 30-second periods where he spaces out and chuckles, partial-onset seizures vary from person to person and can also present as twitching or a sudden emotional swing.  

"Almost 60 percent of people who have seizures experience partial-onset seizures,3 and while some have trademark characteristics like Jeff's that make them easier to identify, others might be barely perceptible, even to the person having them," said Kelly Simontacchi, Ph.D., Medical Director, CNS at UCB. "Even the most subtle partial-onset seizures cannot and should not be taken lightly."

A critical step for people experiencing partial-onset seizures may be to seek care from a specialist, who can help them manage their condition.

"My personal Pledge was going the extra mile to seek out the best health care team I could find and have the most productive conversations with them as possible," said Klauk, whose first partial-onset seizure occurred as he was driving his family to church. "Epilepsy is not something to hide from. I encourage others affected by partial-onset seizures to speak candidly with their doctors and loved ones, and go online to take their own Pledge."

UCB's Pledge campaign isn't just for those living with epilepsy. Caregivers, who are often on the front lines of epilepsy management with their loved ones, are also invited to take the Pledge.

"I took the Pledge for the one I love the most, and constantly strive to better understand the condition and how it impacts Jeff," said Shanna Klauk, Jeff's wife and the one he credits as his 'anchor' in helping him to manage his condition. "Standing outside Jeff's condition gives me a perspective that he doesn't have. The vantage point of a family member or loved one can be invaluable to someone living with epilepsy, both in the doctor's office and in everyday life." 

UCB, a leader in epilepsy and the maker of VIMPAT®, an add-on medication used to treat partial-onset seizures in adults with epilepsy, is committed to transforming the lives of people living with severe diseases through conducting scientific research, developing treatments and creating programming for health care professionals and patients. The company's latest initiative is a simple but important step in helping the epilepsy community obtain additional or improved seizure control and encourages the public to shift their mindset, take action and support a nationwide movement of people ready to do more.  Pledges can range from improving communication, educating friends and family about epilepsy or encouraging others not to settle for their current level of seizure control.  More information and tips for living the Pledge can be found online


VIMPAT® (lacosamide) is a prescription medicine that is used with other medicines to treat partial onset seizures in people 17 years of age and older with epilepsy.


VIMPAT® may not be for everyone. Ask your healthcare provider if VIMPAT® is right for you.


Antiepileptic drugs, including VIMPAT®, may cause suicidal thoughts or actions in a very small number of people, about 1 in 500. Call your healthcare provider right away if you have new or worsening symptoms of depression, any unusual changes in mood or behavior, or suicidal thoughts, behavior, or thoughts about self-harm that you have never had before or may be worse than before.

Do not stop taking VIMPAT® without first talking to your healthcare provider. Stopping VIMPAT® suddenly can cause serious problems. Stopping seizure medicine suddenly in a patient who has epilepsy can cause seizures that will not stop.

VIMPAT® may also cause you to feel dizzy, have double vision, feel sleepy, or have problems with coordination and walking. You should not drive, operate machinery or do other dangerous activities until you know how VIMPAT® affects you.

VIMPAT® may cause you to have an irregular heartbeat or may cause you to feel faint. Call your healthcare provider if you have a fast, slow, or pounding heartbeat, shortness of breath, feel lightheaded, or if you fainted or feel like you are going to faint.

VIMPAT® is a federally controlled substance (C-V) because it can be abused or lead to drug dependence. Keep your VIMPAT® in a safe place to protect it from theft. Do not give it to anyone else, because it may harm them.

In rare cases, VIMPAT® may cause a serious allergic reaction that may affect your skin or other parts of your body such as your liver or blood cells. Call your healthcare provider right away if you have a skin rash or hives, fever or swollen glands that do not go away, shortness of breath, swelling of the legs, yellowing of the skin or whites of the eyes, or dark urine.

Before taking VIMPAT®, tell your healthcare provider if you have or have had depression, mood problems, or suicidal thoughts or behavior; have heart, kidney or liver problems; have abused prescription medicines, street drugs or alcohol in the past, are pregnant or plan to become pregnant.

Common Adverse Reactions

In clinical trials, the most common side effects seen with VIMPAT® were dizziness, headache, nausea, and double vision.

Talk to your healthcare provider about other possible side effects with VIMPAT®. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit, or call 1-800-FDA-1088. 

Please see additional patient information in the Medication Guide at the end of the full prescribing information. This information does not take the place of talking with your healthcare provider about your condition or your treatment. Visit for more information.

About Epilepsy

Epilepsy is a chronic neurological disorder affecting approximately 65 million people worldwide and 3 million people in the U.S.—making it more common than autism, cerebral palsy, multiple sclerosis and Parkinson's disease combined. Anyone can develop epilepsy; it occurs across all ages, races and genders and is defined as two or more unprovoked seizures. Uncontrolled seizures and medication side effects pose challenges to independent living, learning and employment, so the goal of epilepsy treatment is seizure freedom with minimal side effects. More than 1 million patients in the U.S. continue to have seizures despite initial therapy, and more than 800,000 patients in the U.S. continue to have seizures despite treatment with two or more therapies. New medications and treatments give hope to those living with uncontrolled seizures.1,4

About UCB

UCB, Brussels, Belgium ( is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With 9,000 people in approximately 40 countries, the company generated revenue of EUR 3.4 billion in 2012. UCB is listed on Euronext Brussels (symbol: UCB).

For more information
Andrea Levin 

Julia Jackson


1. accessed 3/16/13

2. Epilepsy Foundation. FIND A DOCTOR. Accessed April 3, 2013.

3. Vimpat. Understanding Partial-Onset Seizures. Accessed April 8, 2013.

4. NINDS/NIH. Seizures and Epilepsy. Accessed April 3, 2013.

Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. The Lancet Makes Research More Accessible for Healthcare Professionals With New App for iPad
2. New Study: Health Professionals Support Biotechnologys Use In Food Products And Sustainable Farming
3. Life Science Professionals: Annual Career Fair Announced
4. Elsevier Launches a New Product Literature Database Solution for Life Science Professionals
5. CfPIE’s Newest Training Course Facilitates Life Science Professionals in Staying Current with FDA Approval Trends
6. RAPS, Eucomed Partner to Provide Online Training to Regulatory Professionals Throughout Europe
7. Brownfield Science & Technology Inc. Honored for Professional Services Excellence
8. Verified Clinical Trials Will Exhibit at the Annual 2013 SCOPE Summit to Discuss the Professional Research Subject and the Clinical Trial Database Registry
9. Wake Forest Innovations Partners with Veterinary Bioscience Institute to Develop Educational Programs for Life Science Professionals
10. Touch Medical Media Splits From Touch Briefings, Launches a Series of Cutting Edge, Free to Access, Educational Resources and Signs an Updated Media Partnership With ECCO, The European CanCer Organisation Representing 60,000 Oncology Professionals
11. Innovative semiconductor device researcher at NJIT to receive professional award
Post Your Comments:
(Date:10/10/2017)... Los Angeles, CA (PRWEB) , ... ... ... Pharmaceuticals, Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) ... all uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed ...
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... ... innovation and business process optimization firm for the life sciences and healthcare industries, ... conference in San Francisco. , The presentation, “Automating GxP Validation for Agile ...
(Date:10/9/2017)... ... October 09, 2017 , ... ... of medical marijuana products targeting the needs of consumers who are incorporating medical ... takes place in Phoenix, Arizona. , As operators of two successful Valley dispensaries, ...
(Date:10/6/2017)... ... October 06, 2017 , ... ... healthcare and technology sector at their fourth annual Conference where founders, investors, innovative ... speakers and the ELEVATE pitch competition showcasing early stage digital health and med ...
Breaking Biology Technology:
(Date:4/11/2017)... DUBLIN , Apr. 11, 2017 Research ... Tracking Market 2017-2021" report to their offering. ... The global eye tracking market to grow at ... The report, Global Eye Tracking Market 2017-2021, has been prepared based ... report covers the market landscape and its growth prospects over the ...
(Date:4/5/2017)... SEATTLE , April 5, 2017  The Allen ... the Allen Cell Explorer: a one-of-a-kind portal and dynamic ... large-scale 3D imaging data, the first application of deep ... edited human stem cell lines and a growing suite ... the platform for these and future publicly available resources ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
Breaking Biology News(10 mins):